Pharma

#Biobanking #Imaging #Immuno-oncology #Online focus #PET technology #Pharma #Phenomics #Tumour biology

Multimodal PET yields novel insights in preclinical oncology

By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression… Read More

#Exclusive Content #News

#Cell and gene therapy #ELRIG #Events #Pharma

First ELRIG meeting on Cell & Gene Therapy

The ELRIG Cell & Gene Therapy meeting will be held virtually on May 18-19, 2021. This interactive two-day conference will host scientists from academia and industry to discuss current and future perspectives of cell and gene therapies. Cell and gene therapies are rapidly evolving, revealing many new therapeutic opportunities not… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Biotechnology #CRISPR #Drug delivery #Drug discovery #Genetics / genomics #Pharma

ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 license agreement

ERS Genomics and Nuvisan Innovation Campus Berlin (ICB), an integrated contract research service provider for drug discovery and early development programs, have announced a non-exclusive license agreement granting Nuvisan ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. Nuvisan ICB originated from a spin-out of the major pharma R&D functions of… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Drug design #Pharma #Pharmaceuticals #Regulatory

Biotech consultancy has recruitment drive following surge in demand

Turnover at pharmaceutical and biotech product development consultancy Boyds has surged by 25% as demand for its specialist services continues to grow. The company has added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles… Read More

#News

#Biotechnology #Life sciences #Pharma #Report #Therapeutics

Report shows growth in advanced therapeutics in Stockholm

A new report from Invest Stockholm on Advanced Therapeutics Manufacturing and Life Science in the Stockholm region showed that the sector has grown by 66% in the past four years. Collaboration between local tech and pharma industries are expected to further enhance Stockholm’s competitiveness and growth in the future. Both… Read More

#Editor's Choice #News #Trending News